




The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Liabilities, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 75% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	2,485,196
Cost of Goods Sold	0
Intangible Assets	13,628
Liabilities, Current	416,026
Liabilities, Non-Current	763,640
Other Assets	295,464
Other Compr. Net Income	-47
Other Expenses	65,107
Other Liabilities	1,043,293
Other Net Income	11,098
Other Revenues	540,099
Property and Equipment	190,430
Research and Development	722,343
Selling, General and Administrative Expense	317,875

Output Variable	Value in 1000 USD
Assets	2,984,718
Liabilities	2,222,959
Expenses	1,105,325
Revenues	540,099
Stockholders Equity	761,759
Net Income	-554,128
Comprehensive Net Income	-554,152
BaseVar	3,432,123
ECR before Limited Liability	42%
Economic Capital Ratio	182%